Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Baudax Bio, Inc.
  6. Summary
    BXRX   US07160F4046

BAUDAX BIO, INC.

(BXRX)
  Report
Real-time Estimate Cboe BZX  -  02:51:09 2023-02-06 pm EST
3.270 USD   -3.82%
02/01Certain common stock of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2023.
CI
02/01Certain warrants of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2023.
CI
02/01Certain restricted stock units of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2023.
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/31/2023 02/01/2023 02/02/2023 02/03/2023 02/06/2023 Date
2.95(c) 3.11(c) 3.28(c) 3.4(c) 3.26 Last
258 994 454 768 448 095 935 398 179 628 Volume
-1.99% +5.42% +5.47% +3.66% -4.12% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 0,96 M - -
Net income 2022 -55,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,02x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -19,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,77x
Yield 2023 -
Capitalization 1,89 M 1,89 M -
Capi. / Sales 2022 1,97x
Capi. / Sales 2023 -
Nbr of Employees 80
Free-Float 99,7%
More Financials
Company
Baudax Bio, Inc. is a pharmaceutical company. The Company is primarily focused on commercializing and developing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. This injectable form of IV meloxicam, utilizes NanoCrystal... 
More about the company
All news about BAUDAX BIO, INC.
02/01Certain common stock of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1..
CI
02/01Certain warrants of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB..
CI
02/01Certain restricted stock units of Baudax Bio, Inc. are subject to a Lock-Up Agreement E..
CI
02/01Certain options of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-..
CI
01/24Baudax Bio, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/24Top Midday Gainers
MT
01/24Baudax Bio Reports Positive Outcome of Initial Analysis in Phase 2 Trial of BX1000; Sha..
MT
01/24Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial ..
AQ
01/24Baudax Bio, Inc. Announces Positive Outcome of Interim Analysis of Phase Ii Randomized ..
CI
01/09Baudax Bio : Corporate Overview
PU
01/09Baudax Bio, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/04North American Morning Briefing: Futures Rise -2-
DJ
01/03Noble Capital Downgrades Baudax Bio to Market Perform Rating From Outperform
MT
2022Baudax Bio, Inc. : Other Events (form 8-K)
AQ
2022Top Premarket Gainers
MT
More news
News in other languages on BAUDAX BIO, INC.
01/24Principaux gagnants de la mi-journée
01/24Baudax Bio annonce les résultats positifs de l'analyse initiale de l'essai de phase 2 d..
01/24Baudax Bio, Inc. Annonce le résultat positif de l'analyse intermédiaire de l'essai rand..
2022Principaux gagnants du pré-marché
2022Wall street devrait ouvrir en hausse alors que les investisseurs attendent les données ..
More news
Analyst Recommendations on BAUDAX BIO, INC.
More recommendations
Chart BAUDAX BIO, INC.
Duration : Period :
Baudax Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUDAX BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 3,40 $
Average target price 24,00 $
Spread / Average Target 606%
EPS Revisions
Managers and Directors
Gerri A. Henwood President, Chief Executive Officer & Director
Jillian Dilmore Chief Financial & Accounting Officer
Wayne B. Weisman Chairman
Stewart Mccallum Chief Medical Officer
William L. Ashton Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BAUDAX BIO, INC.6.92%2
MODERNA, INC.-3.55%66 559
LONZA GROUP AG21.92%44 368
IQVIA HOLDINGS INC.15.76%44 054
ALNYLAM PHARMACEUTICALS, INC.-1.80%28 711
SEAGEN INC.7.38%25 622